Skip to main content

Advertisement

SpringerLink
Log in

Advances in Treatment of Waldenström Macroglobulinemia

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The discovery of recurring somatic mutations, in particular MYD88 and CXCR4 mutations, in Waldenström macroglobulinemia (WM), a rare B-cell lymphoproliferative disorder, led in the last decade to the development of several therapeutic agents with high efficacy. This review aims to provide an overview of available treatments in WM and novel agents, focusing on studies published over recent years.

Recent Findings

There is no international consensus on the best first-line option in treatment-naïve patients. Randomized clinical trials are rare in WM and there has been no prospective comparison of chemoimmunotherapy and BTK inhibitors in the frontline setting.

Summary

Chemoimmunotherapy and BTK inhibitors, the two feasible and most widely used treatments in first-line treatment, represent very different options in terms of duration of therapy, route of administration, cost, and adverse effect. In addition to tumor genotype and patient comorbidities, choice of therapy in WM should take into account these parameters. Results of ongoing and future clinical trials evaluating fixed-duration combinations with BTK inhibitors and novel agents are awaited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, et al. Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38(11):1198–208. https://doi.org/10.1200/JCO.19.02314. This article is a comprehensive review on how recent genomic discoveries have influenced treatment progress in WM.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016;127(25):3237–52. https://doi.org/10.1182/blood-2016-01-695098.

    Article  CAS  PubMed  Google Scholar 

  3. Roccaro AM, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123(26):4120–31. https://doi.org/10.1182/blood-2014-03-564583.

    Article  CAS  PubMed  Google Scholar 

  4. Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D’Sa S, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström macroglobulinaemia. Lancet Haematol. 2020;7(11):e827–37. https://doi.org/10.1016/S2352-3026(20)30224-6. This is the latest recommendations on treatment in WM.

    Article  PubMed  Google Scholar 

  5. Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, ESMO Guidelines Committee, et al. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv41–50. https://doi.org/10.1093/annonc/mdy146. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270. Erratum in: Ann Oncol. 2019 May 1;30(5):860-862.

    Article  CAS  PubMed  Google Scholar 

  6. NCCN Guidelines Version 2.2019 WM/LPL; National Comprehensive Cancer Network (NCCN): Plymouth Meeting, PA, USA, 2019.

  7. Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström’s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022;40(1):52–62. https://doi.org/10.1200/JCO.21.00838.

    Article  CAS  PubMed  Google Scholar 

  8. Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126(11):1392–4. https://doi.org/10.1182/blood-2015-05-647420.

    Article  PubMed  Google Scholar 

  9. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25(22):3344–9. https://doi.org/10.1200/JCO.2007.10.9926.

    Article  CAS  PubMed  Google Scholar 

  10. Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, et al. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. Br J Haematol. 2017;179(1):98–105. https://doi.org/10.1111/bjh.14826.

    Article  CAS  PubMed  Google Scholar 

  11. Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018;181(1):77–85. https://doi.org/10.1111/bjh.15148.

    Article  CAS  Google Scholar 

  12. Abeykoon JP, Zanwar S, Ansell SM, Muchtar E, He R, Greipp PT, et al. Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. Am J Hematol. 2021;96(8):945–53. https://doi.org/10.1002/ajh.26210.

    Article  CAS  PubMed  Google Scholar 

  13. Buske C, Dimopoulos MA, Grunenberg A, Kastritis E, Tomowiak C, Mahé B, et al. Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for waldenström's macroglobulinemia: A prospectively randomized trial of the European Consortium for Waldenström's Macroglobulinemia. J Clin Oncol. 2023;41(14):2607–2616. https://doi.org/10.1200/JCO.22.01805. This recent randomized study demonstrates the efficacy and safety of fixed-duration immunochemotherapy and highlights the role of PI to induce faster response and improve overall response rate.

  14. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10. https://doi.org/10.1016/S0140-6736(12)61763-2. Erratum in: Lancet. 2013 Apr 6;381(9873):1184

    Article  CAS  PubMed  Google Scholar 

  15. Uppal E, Khwaja J, Bomsztyk J, McCarthy H, Kothari J, Walton P, et al. Registry for Waldenström macroglobulinaemia: The growth of a national registry for a rare disorder. Br J Haematol. 2023. https://doi.org/10.1111/bjh.18680.

  16. Tohidi-Esfahani I, Warden A, Malunis E, DeNardis PL, Haurat J, Black M, et al. WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes. Am J Hematol. 2021;96(6):E218–22. https://doi.org/10.1002/ajh.26173.

    Article  PubMed  Google Scholar 

  17. Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, et al. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019;186(1):146–9. https://doi.org/10.1111/bjh.15718.

    Article  PubMed  Google Scholar 

  18. Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol. 2018;97(8):1417–25. https://doi.org/10.1007/s00277-018-3311-z.

    Article  CAS  PubMed  Google Scholar 

  19. Arulogun SO, Brian D, Goradia H, Cooney A, Menne T, Koo R, et al. Bendamustine plus rituximab for the treatment of Waldenström macroglobulinemia: Patient outcomes and impact of bendamustine dosing. Am J Hematol. 2023. https://doi.org/10.1002/ajh.26895. This recently published study reports a large cohort of patients treated with BR and confirmed the efficacy of this treatment.

  20. Rummel MJ, Lerchenmüller C, Hensel M, Goerner M, Buske C, Schulz H, et al. two years rituximab maintenance vs. observation after first line treatment with Bendamustine plus Rituximab (B-R) in patients with Waldenström's Macroglobulinemia (MW): Results of a prospective, randomized, multicenter phase 3 study (the StiL NHL7-2008 MAINTAIN trial). Blood. 2019;134(Supplement_1):343. First randomized study showing no PFS and OS benefit of rituximab maintenance after BR.

    Article  Google Scholar 

  21. Zanwar S, Abeykoon J, Castillo J, Durot E, Kastritis E, Uppal E, et al. A multicenter, international collaborative study evaluating frontline therapy with bendamustine rituximab for Waldenström macroglobulinemia. HemaSphere. 2022;6:1046–7. https://doi.org/10.1097/01.HS9.0000847504.29146.b9.

    Article  PubMed Central  Google Scholar 

  22. Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017;129(4):456–9. https://doi.org/10.1182/blood-2016-09-742411. Erratum in: Blood. 2022 Mar 17;139(11):1772

    Article  CAS  PubMed  Google Scholar 

  23. Treon S, Meid K, Gustine J, Patterson CJ, Matous JV, Ghobrial I, Castillo JJ. Long-term outcome of a prospective study of bortezomib, dexamethasone and rituximab (BDR) in previously untreated, symptomatic patients with Waldenstrom's macroglobulinemia. Blood. 2015;126(23):1833.

    Article  Google Scholar 

  24. Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1422–8. https://doi.org/10.1200/JCO.2009.25.3237.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Meid K, Dubeau T, Severns P, Gustine J, Ghobrial IM, Castillo JJ, Treon SP. Long-term follow-up of a prospective clinical trial of carfilzomib, rituximab and dexamethasone (CaRD) in Waldenstrom's macroglobulinemia. Blood. 2017;130(Supplement 1):2772.

    Google Scholar 

  26. Castillo JJ, Meid K, Flynn CA, Chen J, Demos MG, Guerrera ML, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv. 2020;4(16):3952–9. https://doi.org/10.1182/bloodadvances.2020001963.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kersten MJ, Amaador K, Minnema MC, Vos JMI, Nasserinejad K, Kap M, et al. Combining ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenström's macroglobulinemia: final analysis of the phase I/II HOVON124/ECWM-R2 study. J Clin Oncol. 2022;40(1):40–51. https://doi.org/10.1200/JCO.21.00105.

    Article  CAS  PubMed  Google Scholar 

  28. Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, et al. CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020;95(4):E95–8. https://doi.org/10.1002/ajh.25730.

    Article  PubMed  Google Scholar 

  29. Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia. J Clin Oncol. 2018;36(27):2755–61. https://doi.org/10.1200/JCO.2018.78.6426.

    Article  CAS  PubMed  Google Scholar 

  30. Castillo JJ, Meid K, Gustine JN, Leventoff C, White T, Flynn CA, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022;36(2):532–9. https://doi.org/10.1038/s41375-021-01417-9.

    Article  CAS  PubMed  Google Scholar 

  31. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;372(15):1430–40. https://doi.org/10.1056/NEJMoa1501548.

    Article  CAS  PubMed  Google Scholar 

  32. Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol. 2021;39(6):565–75. https://doi.org/10.1200/JCO.20.00555. This study is the actualization of the pivotal phase 2 study leading to the approval of ibrutinib in WM.

    Article  CAS  PubMed  Google Scholar 

  33. Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–37. https://doi.org/10.1182/blood.2020006449. Erratum in: Blood. 2021 Feb 25;137(8):1131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Tam CS, Opat S, D’Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–50. https://doi.org/10.1182/blood.2020006844. First randomized study between 2 BTKi reporting comparable efficacy but a better toxicity profile for zanubrutinib.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4(23):6009–18. https://doi.org/10.1182/bloodadvances.2020003010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7(2):e112–21. https://doi.org/10.1016/S2352-3026(19)30210-8. Erratum in: Lancet Haematol. 2021 Apr;8(4):e249

    Article  PubMed  Google Scholar 

  37. Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, et al. Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia. Cancer Sci. 2022 Jun;113(6):2085–96. https://doi.org/10.1111/cas.15344.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Cao XX, Jin J, Fu CC, Yi SH, Zhao WL, Sun ZM, et al. Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study. EClinicalMedicine. 2022;4(52):101682. https://doi.org/10.1016/j.eclinm.2022.101682.

    Article  Google Scholar 

  39. Abeykoon JP, Kumar S, Castillo JJ, D’Sa S, Kastritis E, Durot E, et al. Bendamustine rituximab (BR) versus ibrutinib (ibr) as primary therapy for Waldenström macroglobulinemia (WM): an international collaborative study. J Clin Oncol. 2022;40(16_suppl):7566–6.

    Article  Google Scholar 

  40. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901. https://doi.org/10.1016/S0140-6736(21)00224-5.

    Article  CAS  PubMed  Google Scholar 

  41. Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, et al. Venetoclax in previously treated Waldenström macroglobulinemia. J Clin Oncol. 2022;40(1):63–71. https://doi.org/10.1200/JCO.21.01194. This article highlighted the efficacy and safety of venetoclax in WM, even in patients previously exposed to BTKi.

    Article  CAS  PubMed  Google Scholar 

  42. Treon SP, Meid K, Hunter ZR, Flynn CA, Sarosiek SR, Leventoff CR, et al. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. Blood. 2021;138(17):1535–9. https://doi.org/10.1182/blood.2021012953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Treon SP, Buske C, Thomas SK, Castillo JJ, Branagan AR, Dimopoulos MA, et al. Preliminary clinical response data from a phase 1b study of mavorixafor in combination with ibrutinib in patients with Waldenström's macroglobulinemia with MYD88 and CXCR4 mutations. Blood. 2021;138(Supplement 1):1362.

    Article  Google Scholar 

  44. Tomowiak C, Poulain S, Herbaux C, Perrot A, Mahé B, Morel P, et al. Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood Adv. 2021;5(9):2438–46. https://doi.org/10.1182/bloodadvances.2020003895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Castillo JJ, Sarosiek S, Branagan AR, Sermer DJ, Flynn CA, Leventoff C, et al. Ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia. Blood. 2022;140(Supplement 1):564–5. The combination of venetoclax and ibrutinib, already studied in chronic lymphocytic leukemia, is associated with a high efficacy in WM but a higher-than-expected rate of cardiovascular toxicity.

    Article  Google Scholar 

  46. Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016;127(25):3237–52. https://doi.org/10.1182/blood-2016-01-695098.

    Article  CAS  PubMed  Google Scholar 

  47. Castillo JJ, Sarosiek S, Flynn CA, Leventoff C, Little M, White T, et al. A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib. EJHaem. 2022;3(3):927–9. https://doi.org/10.1002/jha2.493.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ailawadhi S, Chanan-Khan AAA, Peterson JL, Longcor J, Oliver K, Brown MF, et al. Treatment free remission (TFR) and overall response rate (ORR) results in patients with relapsed/refractory Waldenstrom’s macroglobulinemia (WM) treated with CLR 131. J Clin Oncol. 2021;39(15_suppl):7561–1.

    Article  Google Scholar 

  49. Othman J, Verner E, Tam CS, Huang J, Lin L, Hilger J, et al. Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia. Haematologica. 2018;103(5):e223–5. https://doi.org/10.3324/haematol.2017.186817.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Palomba ML, Qualls D, Monette S, Sethi S, Dogan A, Roshal M, et al. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. J Immunother Cancer. 2022;10(2):e004128. https://doi.org/10.1136/jitc-2021-004128.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):678–89. https://doi.org/10.1016/S1470-2045(21)00145-5. Erratum in: Lancet Oncol. 2021 Jun;22(6):e239

    Article  CAS  PubMed  Google Scholar 

  52. Castillo JJ, Libby EN, Ansell SM, Palomba ML, Meid K, Flynn CA, et al. Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Adv. 2020;4(20):5089–92. https://doi.org/10.1182/bloodadvances.2020003087.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Jeffrey Arsham, an American medical translator under contract at the Poitiers CHU, for reviewing our original English-language document.

Author information

Authors and Affiliations

  1. Hématologie Clinique, CHU de Reims Et UFR Médecine, Reims, France

    Eric Durot

  2. Service d’Onco-Hématologie Et Thérapie Cellulaire, CIC INSERM 1402, CHU de Poitiers, Poitiers, France

    Cécile Tomowiak

Authors
  1. Eric Durot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cécile Tomowiak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Durot.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Durot, E., Tomowiak, C. Advances in Treatment of Waldenström Macroglobulinemia. Curr Oncol Rep 25, 1375–1386 (2023). https://doi.org/10.1007/s11912-023-01459-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-023-01459-5

Keywords

Search

Navigation